Litcius/Paper detail

Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy

Liang Zhang, Boxin Zhang, Mengjie Zhang, Wenlang Li, Hao Li, Yantian Jiao, Qi‐Chao Yang, Shuo Wang, Yuan‐Tong Liu, An Song, Hai‐Tao Feng, Jianwei Sun, Ryan T. K. Kwok, Jacky W. Y. Lam, Ben Zhong Tang, Zhi‐Jun Sun

2025Nature Communications32 citationsDOIOpen Access PDF

Abstract

The discovery of tertiary lymphoid structures (TLS) within tumor tissues provides a promising avenue to promote the efficacy of cancer immunotherapy. Yet, the lack of effective strategies to induce TLS formation poses a substantial obstacle. Thus, the exploration of potential inducers for TLS formation is of great interest but remains challenging. Here, inspired by the mechanism of artificially cultivated pearls, a covalent organic framework (COF) is employed to induce TLS formation. Single-cell sequencing analysis reveals that this is achieved by promotion of cytokine hypersecretion, which facilitates the maturation, proliferation, and migration of T and B cells, critical for triggering TLS formation. Furthermore, the efficacy of COF-mediated phototherapy in inducing TLS formation is validated in both the MC38 and 4MOSC1 female tumor models. Notably, a strong synergistic effect between COF-mediated phototherapy and αCTLA-4 is observed, resulting in the effective eradication of both primary and distant tumors, while also inhibiting tumor recurrence. The formation of tertiary lymphoid structures (TLS) is promising for boosting cancer immunotherapy, but it is challenging to develop potential inducers for TLS formation. Here, the authors report a covalent organic framework (COF) that is able to trigger TLS formation.

Topics & Concepts

ImmunotherapyCancer immunotherapyCancer researchCancerChemistryCovalent bondMedicineInternal medicineOrganic chemistryImmune cells in cancerCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction
Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy | Litcius